Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 1
1998 1
2000 1
2003 1
2005 3
2006 1
2007 1
2009 1
2012 1
2013 2
2014 2
2015 3
2016 1
2018 3
2019 1
2020 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

24 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA.
Scheel B, Aulwurm S, Probst J, Stitz L, Hoerr I, Rammensee HG, Weller M, Pascolo S. Scheel B, et al. Eur J Immunol. 2006 Oct;36(10):2807-16. doi: 10.1002/eji.200635910. Eur J Immunol. 2006. PMID: 17013976 Free article.
We wanted to find out whether this danger signal is capable of triggering anti-tumor immunity when injected locally into an established tumor. ...Residual RNA-injected tumors show CD8 infiltration. Distant injections of prot …
We wanted to find out whether this danger signal is capable of triggering anti-tumor immunity when injected
Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Mullins SR, Vasilakos JP, Deschler K, Grigsby I, Gillis P, John J, Elder MJ, Swales J, Timosenko E, Cooper Z, Dovedi SJ, Leishman AJ, Luheshi N, Elvecrog J, Tilahun A, Goodwin R, Herbst R, Tomai MA, Wilkinson RW. Mullins SR, et al. J Immunother Cancer. 2019 Sep 11;7(1):244. doi: 10.1186/s40425-019-0724-8. J Immunother Cancer. 2019. PMID: 31511088 Free PMC article.
BACKGROUND: Immune checkpoint blockade (ICB) promotes adaptive immunity and tumor regression in some cancer patients. ...CONCLUSION: Localized TLR7/8 agonism can enhance recruitment and activation of immune cells in tumors and polarize anti-t
BACKGROUND: Immune checkpoint blockade (ICB) promotes adaptive immunity and tumor regression in some cancer patients. . …
Anti-tumor immunity elicited by direct intratumoral administration of a recombinant adenovirus expressing either IL-28A/IFN-lambda2 or IL-29/IFN-lambda1.
Hasegawa K, Tagawa M, Takagi K, Tsukamoto H, Tomioka Y, Suzuki T, Nishioka Y, Ohrui T, Numasaki M. Hasegawa K, et al. Cancer Gene Ther. 2016 Aug;23(8):266-77. doi: 10.1038/cgt.2016.29. Epub 2016 Aug 19. Cancer Gene Ther. 2016. PMID: 27561689
Interleukin (IL)-28A/interferon (IFN)-lambda2 and IL-29/IFN-lambda1 have been demonstrated to elicit direct and indirect anti-tumor actions. In this study, we constructed an adenovirus vector expressing either IL-28A/IFN-lambda2 (AdIL-28A) or IL-29/IFN-lambda1 (AdIL …
Interleukin (IL)-28A/interferon (IFN)-lambda2 and IL-29/IFN-lambda1 have been demonstrated to elicit direct and indirect anti-tumo
Generation of potent anti-tumor immunity in mice by interleukin-12-secreting dendritic cells.
Hüttner KG, Breuer SK, Paul P, Majdic O, Heitger A, Felzmann T. Hüttner KG, et al. Cancer Immunol Immunother. 2005 Jan;54(1):67-77. doi: 10.1007/s00262-004-0571-3. Cancer Immunol Immunother. 2005. PMID: 15693141
This anti-tumor immune response was most pronounced when using recombinant protein as an antigen source, which was evident in a prophylactic as well as in a therapeutic setting. The absence of a response to parental K-Balb tumors confirmed the antigen …
This anti-tumor immune response was most pronounced when using recombinant protein as an antigen source, which was evid …
Injectable polypeptide-engineered hydrogel depot for amplifying the anti-tumor immune effect induced by chemo-photothermal therapy.
Hou XL, Dai X, Yang J, Zhang B, Zhao DH, Li CQ, Yin ZY, Zhao YD, Liu B. Hou XL, et al. J Mater Chem B. 2020 Sep 30;8(37):8623-8633. doi: 10.1039/d0tb01370f. J Mater Chem B. 2020. PMID: 32821893
Bestatin as an immune-adjuvant drug could amplify the body's immune function. The results of in vivo therapy tests exhibited that the Ag2S QD/DOX/Bestatin@PC10ARGD hydrogel with laser irradiation could activate anti-tumor immune effects t …
Bestatin as an immune-adjuvant drug could amplify the body's immune function. The results of in vivo therapy tests exhi …
Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity.
Schettini J, Kidiyoor A, Besmer DM, Tinder TL, Roy LD, Lustgarten J, Gendler SJ, Mukherjee P. Schettini J, et al. Cancer Immunol Immunother. 2012 Nov;61(11):2055-65. doi: 10.1007/s00262-012-1264-y. Epub 2012 Apr 28. Cancer Immunol Immunother. 2012. PMID: 22543528 Free PMC article.
Moreover, MyD88-deficient NK cells can perform ADCC in vitro. Furthermore, intratumoral injections of CpG ODN-conjugated HMFG-2 induced a significant reduction in tumor burden in vivo in an established model of pancreatic tumor in nude mice compared to CpG OD …
Moreover, MyD88-deficient NK cells can perform ADCC in vitro. Furthermore, intratumoral injections of CpG ODN-conjugated HMFG-2 induc …
Chemotherapy based on HPMA copolymer conjugates with pH-controlled release of doxorubicin triggers anti-tumor immunity.
Mrkvan T, Sirova M, Etrych T, Chytil P, Strohalm J, Plocova D, Ulbrich K, Rihova B. Mrkvan T, et al. J Control Release. 2005 Dec 10;110(1):119-29. doi: 10.1016/j.jconrel.2005.09.028. Epub 2005 Nov 2. J Control Release. 2005. PMID: 16269198
A novel class of anti-cancer therapeutics - polymeric conjugates of N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers and doxorubicin with pH-controlled release of the drug - is highly efficient in killing tumor cells in vitro and is potent in eradicating g …
A novel class of anti-cancer therapeutics - polymeric conjugates of N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers and do …
Combining photothermal therapy and immunotherapy against melanoma by polydopamine-coated Al2O3 nanoparticles.
Chen W, Qin M, Chen X, Wang Q, Zhang Z, Sun X. Chen W, et al. Theranostics. 2018 Mar 8;8(8):2229-2241. doi: 10.7150/thno.24073. eCollection 2018. Theranostics. 2018. PMID: 29721075 Free PMC article.
The Al(2)O(3) within the nanoparticles, together with CpG, acts as an adjuvant to trigger robust cell-mediated immune responses that can help eliminate the residual tumor cells and reduce the risk of tumor recurrence. ...After photothermal irradiation …
The Al(2)O(3) within the nanoparticles, together with CpG, acts as an adjuvant to trigger robust cell-mediated immune response …
Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN.
de Jong S, Chikh G, Sekirov L, Raney S, Semple S, Klimuk S, Yuan N, Hope M, Cullis P, Tam Y. de Jong S, et al. Cancer Immunol Immunother. 2007 Aug;56(8):1251-64. doi: 10.1007/s00262-006-0276-x. Epub 2007 Jan 23. Cancer Immunol Immunother. 2007. PMID: 17242927
In this work we investigate the effect of encapsulation on the immunopotency of subcutaneously (s.c.) administered CpG ODN with regard to activation of innate immune cells as well as its ability to act as a vaccine adjuvant with tumor-associated antigens (TAA …
In this work we investigate the effect of encapsulation on the immunopotency of subcutaneously (s.c.) administered CpG ODN with regar …
Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions.
Mortara L, Frangione V, Castellani P, De Lerma Barbaro A, Accolla RS. Mortara L, et al. Int Immunol. 2009 Jun;21(6):655-65. doi: 10.1093/intimm/dxp034. Epub 2009 Apr 24. Int Immunol. 2009. PMID: 19395374
In contrast, only 30% of mice injected with irradiated TS/A parental cells were protected from tumor growth, whereas the remaining 70% of animals remained unprotected. ...These results let to envisage the use of CIITA-transfected non-replicating tumor cells a …
In contrast, only 30% of mice injected with irradiated TS/A parental cells were protected from tumor growth, whereas the remai …
24 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page